Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 80
    records per page

    The impact of vital signs on the death of patients with new coronavirus pneumonia MESHD pneumonia HP: A systematic review and meta-analysis

    Authors: Meixia Du; Jie Zhao; Xiaochun Yin; Nadi Zhang; Guisen Zheng; Jose Guillermo Gonzalez-Valdez; Rocio Ortiz-Lopez; Augusto Rojas-Martinez; Grissel Trujillo-de Santiago; Mario Moises Alvarez; Jacques Demongeot; Renaud Piarroux; Stanislas Rebaudet; Omai B Garner; Yi Yin; Joshua S Bloom; Leonid Kruglyak; Jason M Goldstein; Joel M Montgomery; Christina F Spiropoulou

    doi:10.1101/2020.09.17.20196709 Date: 2020-09-18 Source: medRxiv

    Background: Assessing the impact of vital signs ( blood SERO pressure, body temperature, heart rate, respiratory rate, and oxygen saturation) on the death of patients with new coronavirus pneumonia MESHD pneumonia HP would provide a simple and convenient method for the monitoring of subsequent illness, and therefore, in some degree reduce treatment costs and increase the cure rate clinically. Methods: Six databases were retrieved. The software R 3.6.2 was used for meta-analysis of the included literature. Results: 12 studies were included, which comprise 8996 patients affected with COVID-19 infection MESHD. The meta-analysis study found that blood SERO pressure (MAP, SBP and DBP), heart rate, respiration rate and SpO2 are the risk factors for disease progression in patients with COVID-19. Among them, the increase in MAP and the decrease in SpO2 have the greatest impact on the death of patients with COVID-19 [MAP: MD = 5.66, 95% CI (0.34, 10.98), SpO2: MD = -5.87, 95% CI (-9.17, -2.57), P = 0.0005]. However, comparing the body temperature of the death group and the survival group found that the body temperature was not statistically significant between the two groups [body temperature: MD = 0.21, 95% CI (-0.01, 0.43), P = 0.0661]. Conclusion: The increase in MAP, heart rate and respiratory rate, as well as the decrease in SBP, DBP and SpO2 are all independent risk factors for death MESHD in patients with COVID-19. These factors are simple and easy to monitor, and individualized treatment can be given to patients in time, reducing the mortality rate and improving treatment efficiency.

    Respiratory Rehabilitation After Blood SERO Transfusion in a COVID-19 Patient: A Case Report

    Authors: Mohammad Javad Mousavi; Narges Obeidi; Saeed keshmiri; Farzan Azodi; Jamile Kiyani; Farhad Abbasi

    doi:10.21203/ Date: 2020-09-15 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has been identified as the most crucial threat of the century. Due to severe pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD), the SARS-CoV-2 can cause shortness of breath MESHD, hypoxemia HP hypoxemia MESHD, and the need to mechanical ventilation, intensive care unit (ICU) management, and eventual death MESHD. We have tried to use a non-invasive approach to prevent patient from needing respiratory support with invasive ventilation (IV). Here, for the first time, improvement of oxygen delivery and oxygen saturation levels were observed in a COVID-19 patient using packed red blood SERO cells (PRBCs) transfusion.Case presentation: A 63-year-old man with a history of smoking and addiction who came to our hospital facility with fever HP fever MESHD, shortness of breath MESHD and decreased blood SERO oxygen saturation. High-resolution chest CT revealed bilateral and multifocal ground-glass opacities consistent with COVID-19. Subsequently, the COVID-19 infection was confirmed TRANS infection was confirmed MESHD by real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract. Conclusions: Oxygen delivery and oxygen saturation improvement were observed in the COVID-19 patient, after PRBCs transfusions.

    Diagnosis of Coronavirus disease MESHD by measuring serum SERO concentrations of IL-6 and blood SERO Ferritin

    Authors: Parviz Yazdanpanah; Farzad Vafaei; Saeed Javdansirat; Jalal pouranfard; Sajad Afrouz

    doi:10.21203/ Date: 2020-09-09 Source: ResearchSquare

    Objectives: Coronavirus disease MESHD 2019 (COVID-19) associated by infection MESHD and high death rate. The unresolved questions about the fatality rate of COVID-19 is most probably related to cytokine storm syndrome. There is currently no specific medication. Understanding the pathogenic pathway of this disease will lead to production of treatment and decreases of death MESHD rate. The aim of this study is to investigate changes of peripheral blood SERO parameters (Interleukin-6 and Ferritin) in COVID-19 patients, which may be beneficial in the management of patients.Methods: In this case-control study, we collected data of 270 subjects in two groups including 133 patients with severe type COVID-19 (case) and 137 patients with nonsevere (control) between March 20 and May 21, 2020, and the clinical symptoms and inflammatory indications of patients diagnosed by laboratory test in Shahid Jalil hospital of Yasuj University of medical Sciences were collected to explore potential markers for disease monitoring. The data were analyzed by SPSS software version 20. Descriptive statistics, T-test and bivariate correlation tests were used to analyze. Results: The enrolled COVID-19 patients consisted of 53.4% males TRANS and 46.6% females TRANS with the medium age TRANS of 45.56±18.55 years and there were 50.04% males TRANS and 49.6% females TRANS with the medium age TRANS of 45.59±17.0 years for non COVID-19 patients. There was no significant difference in the age TRANS and sex ratio between two population under study. The proportion interstitial abnormalities MESHD evidenced by CT imaging in COVID-19 patients was 91.0%, while, 4.4% abnormalities was found in non COVID-19 patients. The frequency of positive RT-PCR test for case and control groups were 88.0% and 3.6%, respectively. The mean IL-6 and Ferritin levels and hematological parameters in two groups of patients with COVID-19 and non- COVID-19, were significantly different across all comparisons.There was a direct positively correlated between serum SERO level of IL-6, Ferritin levels and hematological parameters including WBC, Lymphocytes, Neutrophils and Hb, except for platelets (negatively correlate),  with COVID-19. Conclusions: In conclusion, inflammatory markers specifically IL-6 and Ferritin and hematological parameters (WBC, Lymphocytes, Neutrophils, Platelet and Hb) were correlated with the severity of COVID-19. Measurement of IL-6, Ferritin and hematological MESHD indices might be workable tests to diagnosis and prognosis of patients with COVID-19. 

    Spatial Distribution and Time Series Analysis of COVID-19 Pandemic in Italy: A Geospatial Perspective

    Authors: Muhammad Farhan Ul Moazzam; Tamkeen Urooj Paracha; Ghani Rahman; Byung Gul Lee; Nasir Farid; Adnan Arshad

    doi:10.21203/ Date: 2020-09-07 Source: ResearchSquare

    The novel coronavirus pandemic disease MESHD (COVID-19) affected the whole globe, though there is lack of clinical studies and its epidemiological features. But as per the observation, it has been seen that most of COVID-19 infected MESHD patients show mild to moderate symptoms and they get better without any medical assistance due to better immune system to generate antibodies SERO against the novel coronavirus. In this study the active cases, serious cases, recovered cases, deaths MESHD and total confirmed cases TRANS have been analyzed using geospatial technique (IDW) with the time span of 2nd March to 3rd June 2020. As on 3rd June the total number of COVID-19 cases in Italy were 231,238, total deaths 33,310, serious cases 350, recovered cases 158,951 and active cases were 39,177 which has been reported by the Ministry of health, Italy. March 2nd – June 3rd 2020 a sum of 231, 238 cases has been reported in Italy out of which 38.68% cases reported in Lombardia region with death rate of 18% which is high from its national mortality rate followed by Emilia-Romagna (14.89% deaths), Piemonte (12.68% deaths), and Vento (10% deaths). As per the total cases in the region, the highest number of recoveries has been observed in Umbria (92.52%), followed by Basilicata (87%), Valle d'Aosta (86.85%) and Trento (84.54%).  The COVID-19 evolution in Italy has been particularly found in the major urban area i.e. Rome, Milan, Naples, Bologna and Florence. Geospatial technology played a vital role in this pandemic by tracking infected patient, active cases, and the recovered cases. Thus, monitoring and planning using geospatial technique is very important to control COVID-19 spread in the country.

    74 Days Dynamic Changes of Chest CT Images of Coronavirus Disease MESHD 2019 (COVID-19) in Hebei Province, China

    Authors: jianqin Liang; Guizeng Liu; Shuzhuang Yu; Yang Yang; Yanchun Li; Hongli Tian; Zhe Chen

    doi:10.21203/ Date: 2020-09-02 Source: ResearchSquare

    Background Since December 2019, the COVID-19 infection broke MESHD out in many parts of the world with confirmed and death MESHD cases rapidly increasing, which posed a great threat to human life and health. Current nucleic acid detection and antibody testing SERO for the SARS-CoV-2 were the main methods for diagnosis of COVID-19, but not so sensitive, with high false negative rate and missed diagnosis rate. Imaging changes of COVID-19 not only precede symptomatic changes, but also have different imaging characteristics in different periods. We conducted 74 days of dynamic chest CT imaging observation on COVID-19 patients in Hebei province, aiming to understand the dynamic characteristics of the chest CT changes of COVID-19, so as to find the source of infection early, take early intervention measures, and judge the prognosis. Methods Chest CT examinations at intervals 1 to 4 days were conducted for 11 patients with a diagnosis of COVID-19. On the 74th day after onset, chest CT was reexamined to analyze the characteristics of chest CT in each stage. Results Of the 11 cases, 1 case was imported from Wuhan, 10 cases were infected for family clustering after close contact TRANS with confirmed COVID-19 cases. There were 3 ordinary cases, 3 severe cases and 5 critical cases. Among them, 2 critical cases died for old age TRANS and complications of underlying diseases MESHD, while 9 cases were cured by April 7, 2020. The changes of chest CT imaging in 1 child TRANS appeared prior to the clinical symptoms. 1–4 days after onset of the initial symptom were the early stages: Chest CT was mainly characterized by single lung quasi-circular ground glass shadow and fine mesh shadow. 5–10 days were the progressive stages: The lesion spread along the axial interstitium of the bronchi and gradually diffused to the whole lung, and reach the peak on day 6 to 9, which was characterized by consolidation, paving stone sign, halo sign, reversed halo sign, and even ‘white lung’ for the critical patients. The recovery stages began on day 11 after onset: The fiber cord, ground glass and consolidation shadow were gradually absorbed. After 74 days of follow-up, no serious permanent lung injury MESHD was found. Conclusion Chest CT could determine the different stages of COVID-19. Dynamic follow-up chest CT showed a good prognosis of COVID-19 in Hebei Province, China

    Acute kidney injury HP kidney injury MESHD is associated with severe and fatal outcomes in patients with Coronavirus disease MESHD 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies

    Authors: Mohammad Parohan; Sajad Yaghoubi; Mahmoud Djalali; Asal Seraji; Mohammad Hassan Javanbakht; Zahra Mousavi

    doi:10.1101/2020.08.27.20183632 Date: 2020-09-01 Source: medRxiv

    Coronavirus disease MESHD 2019 (COVID-19) is a pandemic impacting 213 countries and territories with more than 17,918,582 cases worldwide. Kidney dysfunction MESHD has been reported to occur in severe and death MESHD cases. This meta-analysis was done to summarize available studies on the association between acute kidney injury HP kidney injury MESHD and severity of COVID-19 infection MESHD. Online databases including Web of Science, PubMed/Medline, Cochrane Library, Scopus and Google Scholar were searched to detect relevant articles up to 1 July 2020, using relevant keywords. To pool data, a random- or fixed-effects model was used based on the heterogeneity between studies. In total, 50 studies with 8,180 COVID-19 confirmed cases TRANS (severe cases=1,823 and death MESHD cases=775), were included in this meta-analysis. Higher serum SERO levels of creatinine (weighted mean difference ( WMD MESHD) for disease severity=5.47 mol/L, 95% CI=2.89 to 8.05, P<0.001 and WMD for mortality=18.32 mol/L, 95% CI=12.88 to 23.75, P<0.001), blood SERO urea nitrogen (BUN) ( WMD MESHD for disease severity=1.10 mmol/L, 95% CI=0.67 to 1.54, P<0.001 and WMD for mortality=3.56 mmol/L, 95% CI=2.65 to 4.48, P<0.001) and lower levels of estimated glomerular filtration rate (eGFR) ( WMD MESHD for disease severity=-15.34 mL/min/1.73 m2, 95% CI=-18.46 to -12.22, P<0.001 and WMD for mortality=-22.74 mL/min/1.73 m2, 95% CI=-27.18 to -18.31, P<0.001) were associated with a significant increase in the severity and mortality of COVID-19 infection MESHD. Acute kidney injury HP kidney injury MESHD, as assessed by kidney biomarkers ( serum SERO creatinine, BUN and eGFR), was associated with severe outcome and death MESHD from COVID-19 infection MESHD.

    Risk factors for SARS-CoV-2 infection MESHD, hospitalisation, and death in Catalonia MESHD, Spain: a population-based cross-sectional study

    Authors: Judit Villar-Garcia; Rosa Maria Vivanco-Hidalgo; Montserrat Cleries; Elisenda Martinez; David Monterde; Pol Perez-Sust; Luis Garcia-Eroles; Carol Sais; Montserrat Moharra; Emili Vela; Jochen Lennerz; Hetal Desai Marble; Lauren L. Ritterhouse; Julie Batten; N. Zeke Georgantas; Rebecca Pellerin; Sylvia Signorelli; Julia Thierauf; Molly Kemball; Christian Happi; Donald S. Grant; Daouda Ndiaye; Katherine J. Siddle; Samar B Mehta; Jason B. Harris; Edward T Ryan; Virginia M. Pierce; Regina C LaRocque; Jacob Lemieux; Pardis Sabeti; Eric Rosenberg; John Branda; Sarah E Turbett; Gail Carson; Malcolm G Semple; Janet T Scott

    doi:10.1101/2020.08.26.20182303 Date: 2020-09-01 Source: medRxiv

    OBJECTIVE To identify the different subpopulations that are susceptible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD and hospitalisation or death MESHD due to coronavirus disease MESHD 2019 (COVID-19) in Catalonia, Spain. DESIGN Cross-sectional study. SETTING Data collected from the Catalan Health Surveillance System (CatSalut) in Catalonia, a region of Spain. PARTICIPANTS Using data collected between 1 March and 1 June 2020, we conducted the following comparative analyses: people infected by SARS-CoV-2 (328 892) vs Catalonia's entire population (7 699 568); COVID-19 cases who required hospitalisation (37 638) vs cases who did not require hospitalisation (291 254); and COVID-19 cases who died during the study period vs cases who did not die during the study period (12 287). MAIN OUTCOME MEASURES Three clinical outcomes related to COVID-19 ( infection MESHD, hospitalisation, or death MESHD). We analysed sociodemographic and environment variables (such as residing in a nursing home) and the presence of previous comorbidities. RESULTS A total of 328 892 cases were considered to be infected with SARS-CoV-2 (4.27% of total population). The main risk factors for the diagnostic were: female TRANS gender TRANS (risk ratio [RR] =1.49; 95% confidence interval [95% CI] =1.48-1.50), age TRANS (45-64 years old; RR=1.02; 95% CI=1.01-1.03), high comorbidity burden (GMA index) (RR=3.03; 95% CI=2.97-3.09), reside in a nursing home (RR=11.82; 95% CI=11.66-11.99), and smoking (RR=1.06; 95% CI=1.05-1.07). During the study period, there were 37 638 (11.4 %) hospitalisations due to COVID-19, and the risk factors were: male TRANS gender TRANS (RR=1.45; 95% CI=1.43-1.48), age TRANS > 65 (RR=2.38; 95% CI=2.28-2.48), very low individual income (RR=1.03; 95% CI=0.97-1.08), and high burden of comorbidities (GMA index) (RR=5.15; 95% CI=4.89-5.42). The individual comorbidities with higher burden were obesity HP obesity MESHD (RR=1.23; 95% CI=1.20-1.25), chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD (RR=1.19; 95% CI=1.15-1.22), heart failure MESHD (RR=1.19; 95% CI=1.16-1.22), diabetes mellitus HP diabetes mellitus MESHD (RR=1.07; 95% CI=1.04-1.10), and neuro-psychiatric MESHD comorbidities (RR=1.06; 95% CI=1.03-1.10). A total of 12 287 deaths (3.73%) were attributed to COVID-19, and the main risk factors were: male TRANS gender TRANS (RR=1.73; 95% CI=1.67-1.81), age TRANS > 65 (RR=37.45; 95% CI=29.23-47.93), residing in a nursing home (RR=9.22; 95% CI=8.81-9.65), and high burden of comorbidities (GMA index) (RR=5.25; 95% CI=4.60-6.00). The individual comorbidities with higher burden were: heart failure MESHD (RR=1.21; 95% CI=1.16-1.22), chronic kidney disease HP chronic kidney disease MESHD (RR=1.17; 95% CI=1.13-1.22), and diabetes mellitus HP diabetes mellitus MESHD (RR=1.10; 95% CI=1.06-1.14). These results did not change significantly when we considered only PCR-positive patients. CONCLUSIONS Female TRANS gender TRANS, age TRANS between 45 to 64 years old, high burden of comorbidities, and factors related to environment (nursing home) play a relevant role in SARS-CoV-2 infection MESHD and transmission TRANS. In addition, we found risk factors for hospitalisation and death MESHD due to COVID-19 that had not been described to date, including comorbidity burden, neuro-psychiatric disorders MESHD, and very low individual income. This study supports interventions for transmission TRANS control beyond stratify-and-shield strategies focused only on protecting those at risk of death. Future COVID-19 studies should examine the role of gender TRANS, the burden of comorbidities, and socioeconomic status in disease transmission TRANS, and should determine its relationship to workplaces, especially healthcare centres and nursing homes.

    Assessment of the potential role of PM2.5/PM10 particles in intensifying the pandemic spread of SARS-CoV-2/COVID-19 in Northern Italy

    Authors: Paolo Di Girolamo

    doi:10.21203/ Date: 2020-08-28 Source: ResearchSquare

    The Severe Acute Respiratory Syndrome CoronaVirus 2 MESHD (SARS-CoV-2), which exploded in Wuhan (Hebei Region, China) in late 2019, has recently spread around the World, causing pandemic effects on humans. Italy, and especially its Northern regions around the Po Valley, has been facing severe effects in terms of infected individuals and casualties (more than 31.000 deaths MESHD and 255. 000 infected people MESHD by mid-May 2020). While the spread and effective impact of the virus is primarily related to the life styles and social habits of the different human communities, environmental and meteorological factors also play a role. Among these, pollution from PM2.5/PM10 particles, which may directly impact on the human respiratory system or act as virus carrier TRANS, thus behaving as potential amplifying factors in the pandemic spread of SARS-CoV-2. Enhanced levels of PM2.5/PM10 particles in Northern Italy were observed over the two month period preceding the virus pandemic spread. Threshold levels for PM10 (<50 µg/m³) were exceeded on 20-35 days over the period January-February 2020 in many areas in the Po Valley, where major effects in terms of infections and casualties occurred, with levels in excess of 80 µg/m³ occasionally observed in the 1-3 weeks preceding the contagious activation around February 25th. Threshold values for PM2.5 indicted in WHO air quality guidelines (<25 µg/m³) were exceeded on more than 40 days over the period January-February 2020 in large portions of the Po Valley, with levels up to 70 µg/m³ observed in the weeks preceding the contagious activation. The evolution of particle matter concentration levels throughout the month of February 2020 was carefully monitored and results are reported in the paper.In this paper PM10 particle measurements are compared with epidemiologic parameters data. Specifically, a statistical analysis is carried out to correlate the infection rate, or incidence of the pathology, the mortality rate and the case fatality rate with PM concentration levels. The study considers epidemiologic data for all 110 Italian Provinces, as reported by the Italian Statistics Institute (ISTAT, 2020), over the period 20 February-31 March 2020. Corresponding PM10 concentration levels were collected from the network of air quality monitoring stations run by different Regional and Provincial Environment Agencies, covering the period 15-26 February 2020. The case fatality rate is found to be highly correlated to the average PM10 concentration, with a correlation coefficient of 0.89 and a slope of the regression line of (6.7±0.3)×10-3 m³/µg, which implies a doubling (from 3 to 6 %) of the mortality rate of infected MESHD patients for an average PM10 concentration increase from 22 to 27 μg/m³. Infection and mortality rates are also found to be correlated with PM10 concentration levels, with correlation coefficients being 0.82 and 0.80, respectively, and the slopes of the regression lines indicating a doubling (from 1 to 2 ‰) of the infection rate and a tripling (from 0.1 to 0.3 ‰) of the mortality rate for an average PM10 concentration increase from 25 to 29 μg/m³. Epidemiologic parameters data were also compared with population density data, but no clear evidence of a mutual correlation between these quantities was found. Considerations on the exhaled particles' sizes and concentrations, their residence times, transported viral dose and minimum infective dose, in combination with PM2.5/PM10 pollution measurements and an analytical microphysical model, allowed assessing the potential role of airborne transmission TRANS through virus-transmitting PM particles, in addition to droplet transmission TRANS, in conveying SARS-CoV-2 in the human respiratory system.

    Epidemiological and Clinical Characteristics of COVID-19 Patients with Cancers MESHD: A Systematic Review and Meta-Analysis of Global Data

    Authors: Xiangy Kong; Yihang Qi; Junjie Huang; Yang Zhao; Yongle Zhan; Xuzhen Qin; Zhihong Qi; Adejare (Jay) Atanda; Lei Zhang; Jing Wang; Yi Fang; Peng Jia; Asieh Golozar; Lin Zhang; Yu Jiang; Wegene Borena; Michael Meyer-Hermann; Dorothee von Laer; David Wyllie

    doi:10.1101/2020.08.20.20177311 Date: 2020-08-22 Source: medRxiv

    Background Data on the prevalence SERO of cancer MESHD in coronavirus disease MESHD 2019 (COVID-19)-infected patients and the severe illness incidence and mortality of COVID-19 patients with cancers MESHD remains unclear. Methods We systematically searched PubMed, Embase, Cochrane Library, and Web of Science, from database inception to July 15, 2020, for studies of patients with COVID-19 infection MESHD that had available comorbidity information on cancer MESHD. The primary endpoint was the pooled prevalence SERO of cancer MESHD in COVID-19 patients and the secondary endpoint was the outcomes of COVID-19-infected cancer MESHD patients with incidence of severe illness and death MESHD rate. We calculated the pooled prevalence SERO and corresponding 95% confidence intervals (95% CIs) using a random-effects model, and performed meta-regression analyses to explore heterogeneity. Subgroup analyses were conducted based on continent, country, age TRANS, sample size and study design. Findings A total of 107 eligible global studies were included in the systematic review. 90 studies with 94,845 COVID-19 patients in which 4,106 patients with cancer MESHD morbidity were included in the meta-analysis for prevalence SERO of cancer MESHD morbidity among COVID-19 patients. 21 studies with 70,969 COVID-19 patients in which 3,351 patients with cancer MESHD morbidity who had severe illness MESHD or death MESHD during the studies. The overall prevalence SERO of cancer MESHD among the COVID-19 patients was 0.07 (95% CI 0.05~0.09). The cancer MESHD prevalence SERO in COVID-19 patients of Europe (0.22, 95% CI 0.17~0.28) was higher than that in Asia Pacific (0.04, 95% CI 0.03~0.06) and North America (0.05, 95% CI 0.04~0.06). The prevalence SERO of COVID-19-infected cancer MESHD patients over 60 years old was 0.10 (95% CI 0.07~0.14), higher than that of patients equal and less than 60 years old (0.05, 95% CI 0.03~0.06). The pooled prevalence SERO of severe illness among COVID-19 patients with cancers MESHD was 0.35 (95% CI 0.27~0.43) and the pooled death rate of COVID-19 patients with cancers MESHD was 0.18 (95% CI 0.14~0.18). The pooled incidence of severe illness of COVID-19 patients with cancers MESHD from Asia Pacific, Europe, and North America were 0.38(0.24, 0.52), 0.36(0.17, 0.55), and 0.26(0.20, 0.31), respectively; and the pooled death rate from Asia Pacific, Europe, and North America were 0.17(0.10, 0.24), 0.26(0.13, 0.39), and 0.19(0.13, 0.25), respectively. Interpretation To our knowledge, this study is the most comprehensive and up-to-date meta-analysis assessing the prevalence SERO of cancer MESHD among COVID-19 patients, severe illness incidence and mortality rate. The prevalence SERO of cancer MESHD varied significantly in geographical continents and ages TRANS. The COVID-19 patients with cancer MESHD were at-risk for severe illness MESHD and a high death rate. The European COVID-19 patients had the highest cancer MESHD prevalence SERO among the three continents examined and were also the most likely to progress to severe illness and death MESHD. Although the Asia Pacific COVID-19 patients had the lowest cancer MESHD prevalence SERO, their severe illness rate was similar to that of European.

    Risk Assessment of SARS-CoV-2 in Antarctic Wildlife MESHD

    Authors: Andrés Barbosa; Arvind Vansani; Virginia Morandini; Wray Grimaldi; Ralph E.T. Vanstreels; Julia I. Diaz; Thierry Boulinier; Meagan Dewar; Daniel Gonzalez-Acuña; Rachel Gray; Clive R. McMahon; Gary Miller; Michelle Power; Amandine Gamble; Michelle Wille

    id:10.20944/preprints202008.0478.v1 Date: 2020-08-21 Source:

    The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has spread rapidly to most parts of the world, causing high numbers of deaths MESHD and significant social and economic impacts. SARS-CoV-2 is a novel coronavirus with a suggested zoonotic origin and with the potential for cross-species transmission TRANS among animals. Antarctica can be considered the only continent free of SARS-CoV-2 although at the end of the 2019-2020 tourist season, at least one SARS-CoV-2 positive tourist visited the Antarctic Peninsula. Therefore, concerns have been expressed regarding the potential human introduction of this virus to the continent through the activities of research or tourism with potential effects including those related to human health, but also the potential for virus transmission TRANS to Antarctic wildlife. This reverse-zoonotic transmission risk TRANS to Antarctic wildlife is assessed considering the available information on host susceptibility, dynamics of the infection MESHD in humans, and contact interactions between humans and Antarctic wildlife. Measures to reduce the risk are proposed as well as the identification of knowledge gaps related to this issue.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.